Does long-term treatment for hyperphenylalaninemia and phenylketonuria create a risk of vitamin B12 nutritional deficiency?

PROCHÁZKOVÁ, Dagmar, Jiří JARKOVSKÝ, Petra KONEČNÁ, Hana BENAKOVÁ and Hana VINOHRADSKÁ. Does long-term treatment for hyperphenylalaninemia and phenylketonuria create a risk of vitamin B12 nutritional deficiency? In Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Lyon, France, JIMD, 2015, 38, Supl. 1, s.87. 2015. ISSN 0141-8955.

Basic information

Original name

Does long-term treatment for hyperphenylalaninemia and phenylketonuria create a risk of vitamin B12 nutritional deficiency?

Authors

PROCHÁZKOVÁ, Dagmar, Jiří JARKOVSKÝ, Petra KONEČNÁ, Hana BENAKOVÁ and Hana VINOHRADSKÁ

Edition

Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Lyon, France, JIMD, 2015, 38, Supl. 1, s.87, 2015

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30209 Paediatrics

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.541

Organization unit

Faculty of Medicine

ISSN

Keywords (in Czech)

vitamin B12 holotranskobalamin PKU HPA

Keywords in English

vitamin B12 holotranscobalamin PKU HPA

---

Abstract

V originále

The present study suggests that adult PKU and HPA patients were at risk of developing vitamin B12 deficiency. The best marker for the monitoring is holotranscobalamin in serum.

In Czech

Dospělí dlouhodobě léčení pacienti s PKU a HPA jsou v riziku nutričního deficitu vitaminu B12. K monitorování je nejvhodnější holotranskobalamin v krvi.